Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DCPS | Q96C86 | 4/20 | 0.69 |
| ▸ | DHFR | P00374 | 15/20 | 0.59 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2125495 | 0.86 | DCPS (0.68) | DCPSDHFRKCNH2 | |
| SCHEMBL2128429 | 0.86 | DCPS (0.72) | DCPSDHFRKCNH2 | |
| SCHEMBL2127292 | 0.85 | DCPS (0.79) | DCPSDHFRKCNH2 | |
| SCHEMBL2127791 | 0.83 | DCPS (1.00) | DCPSDHFRKCNH2 | |
| SCHEMBL30912754 | 0.83 | DCPS (1.00) | DCPSDHFRKCNH2 | |
| SCHEMBL1155078 | 0.82 | DCPS (0.66) | DCPSDHFRKCNH2 | |
| SCHEMBL6477195 | 0.81 | DCPS (0.63) | DCPSDHFRKCNH2 | |
| SCHEMBL15284246 | 0.80 | DCPS (0.62) | DCPSDHFRKCNH2 | |
| SCHEMBL6484468 | 0.79 | DCPS (0.60) | DCPSDHFRKCNH2 | |
| SCHEMBL6485667 | 0.79 | DCPS (0.64) | DCPSDHFRKCNH2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1014953-B1 | FORMULATIONS FOR HYDROPHOBIC PHARMACEUTICAL AGENTS | SUGEN INC (US) | 2012-04-25 | — | — | EP | disclosed |
| US-6911446-B2 | Methods of modulating serine/threonine protein kinase function with quinazoline-based compounds | SUGEN, INC. (US) | 2005-06-28 | — | — | US | disclosed |
| US-6696482-B2 | QUINAZOLINE, NITROTHIAZOLE AND INDOLINONE BASED HYDROPHOBIC FORMULATIONS FOR ORAL ADMINISTRATION FOR TREATING CELL PROLIFERATION DISORDER IN A MAMMAL | SUGEN, INC. | 2004-02-24 | — | — | US | disclosed |
| US-20010014679-A1 | Methods of modulating serine/threonine protein kinase function with quinazoline-based compounds | TANG PENG C (US) | 2001-08-16 | — | — | US | disclosed |
| US-20010012844-A1 | Formulations for hydrophobic pharmaceutical agents | SHENOY NARMADA (US) | 2001-08-09 | — | — | US | disclosed |
| US-6248771-B1 | MIXTURE CONTAINING SURFACTANT; ANTIPROLIFERATIVE AGENTS; KINASE INHIBITOR | SUGEN, INC. | 2001-06-19 | — | — | US | disclosed |
| US-6204267-B1 | Methods of modulating serine/thereonine protein kinase function with quinazoline-based compounds | SUGEN, INC. | 2001-03-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20010012844-A1 | Formulations for hydrophobic pharmaceutical agents | ABCG2, SLC7A5, SLCO4C1 | DCPS 4329/4885DHFR 420/4885KCNH2 815/4885 |
| US-20010014679-A1 | Methods of modulating serine/threonine protein kinase function with quinazoline-based compounds | RAF1, STK3, MKNK1 | DCPS 3645/4885DHFR 1842/4885KCNH2 4444/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.